Showing results (981-990 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|January 7, 2012
The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivoKiyohito Kato, Jian Gong, Hisakazu Iwama, et al.
Molecular Cancer Therapeutics|March 10, 2012
JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cellsOsamu Yamada, Kohji Ozaki, Masaharu Akiyama, et al.
Molecular Cancer Therapeutics|March 10, 2012
Hyperactivation of 4E-binding protein 1 as a mediator of biguanide-induced cytotoxicity during glucose deprivationJunichi Matsuo, Yoshinori Tsukumo, Sakae Saito, et al.
Molecular Cancer Therapeutics|August 24, 2011
Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networksIoannis Prassas, George S Karagiannis, Ihor Batruch, et al.
Molecular Cancer Therapeutics|October 6, 2011
A novel kinase inhibitor of FADD phosphorylation chemosensitizes through the inhibition of NF-κBKatrina A Schinske, Shyam Nyati, Amjad P Khan, et al.
Molecular Cancer Therapeutics|August 25, 2011
Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cellsCarolyn M Klinge, Brandie N Radde, Yoannis Imbert-Fernandez, et al.
Molecular Cancer Therapeutics|July 13, 2011
Synthetic triterpenoid cyano enone of methyl boswellate activates intrinsic, extrinsic, and endoplasmic reticulum stress cell death pathways in tumor cell linesPalaniyandi Ravanan, Renata Sano, Priti Talwar, et al.
Molecular Cancer Therapeutics|October 6, 2011
Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolinesVenita Gresham Watson, Nicholas E Hardison, Tyndall Harris, et al.
Molecular Cancer Therapeutics|July 14, 2011
Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinityQi Zhao, Yang Feng, Zhongyu Zhu, et al.
Molecular Cancer Therapeutics|April 13, 2011
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimensVictor M Rivera, Rachel M Squillace, David Miller, et al.
Pageof 599